Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

NCT03703427 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Pathologic Residual Cancer Cells

Interventions

DRUG: Capecitabine, Oral, 500 Mg
DRUG: Vinorelbine Tartrate Oral

Sponsor

Zhiyong Yu